Fluticort (fluticasone propionate): Uses, Dosage & Side Effects

What it's for (Indications)

Fluticasone propionate topical cream and ointment are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
This includes a broad spectrum of conditions such as eczema (atopic dermatitis), psoriasis, contact dermatitis, seborrheic dermatitis, and other acute or chronic inflammatory skin disorders where corticosteroids are deemed beneficial.
Its application aims to reduce symptoms such as erythema, edema, scaling, and intense itching, thereby improving the patient's comfort and the overall condition of the skin.
The choice between cream and ointment formulations is typically based on the nature of the lesion and the area of application, with ointments often preferred for dry, scaly, or lichenified lesions due to their emollient properties, and creams for moist or intertriginous areas.

Dosage Information

Type	Guideline
Standard	For adults and pediatric patients 3 months of age and older, fluticasone propionate cream or ointment should be applied as a thin film to the affected skin areas once or twice daily, depending on the severity of the condition and as directed by a healthcare professional. The application should be gentle, ensuring the medication is rubbed in completely. Treatment duration should be limited to two consecutive weeks for most conditions to minimize the risk of adverse systemic effects, unless specifically prescribed for a longer period by a physician, with close monitoring. The total weekly dosage should generally not exceed 50 grams for adults. It is crucial to instruct patients on proper application techniques, emphasizing external use only and avoiding contact with eyes, mouth, or other mucous membranes.

Type

Guideline

Standard

For adults and pediatric patients 3 months of age and older, fluticasone propionate cream or ointment should be applied as a thin film to the affected skin areas once or twice daily, depending on the severity of the condition and as directed by a healthcare professional. The application should be gentle, ensuring the medication is rubbed in completely. Treatment duration should be limited to two consecutive weeks for most conditions to minimize the risk of adverse systemic effects, unless specifically prescribed for a longer period by a physician, with close monitoring. The total weekly dosage should generally not exceed 50 grams for adults. It is crucial to instruct patients on proper application techniques, emphasizing external use only and avoiding contact with eyes, mouth, or other mucous membranes.

Safety & Warnings

Common Side Effects

Topical fluticasone propionate, while generally well-tolerated, can cause various local and, less commonly, systemic side effects.
Local reactions occurring at the site of application may include burning, pruritus, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria.
Prolonged use, especially under occlusive dressings or on sensitive skin areas, significantly increases the risk of skin atrophy and striae.
Systemic adverse reactions, though infrequent with proper topical use, can occur due to systemic absorption and include manifestations of Cushing's syndrome, hyperglycemia, and glucosuria, particularly in pediatric patients or with extensive application.

Serious Warnings

Black Box Warning: Serious Warnings: While fluticasone propionate topical formulations do not carry a formal FDA Black Box Warning, it is crucial for healthcare professionals and patients to be aware of significant potential systemic adverse effects. Prolonged use, application to large surface areas, use of occlusive dressings, or use in pediatric patients can lead to considerable systemic absorption. This can result in reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria. Pediatric patients are particularly vulnerable due to their higher skin surface area to body mass ratio and immature skin barrier, making them more susceptible to systemic toxicity and potential growth retardation. Patients should be routinely monitored for signs of HPA axis suppression, and if identified, efforts should be made to gradually withdraw the drug or reduce the frequency of application. This product is strictly for external dermatological use and should not be used orally, ophthalmically, or intravaginally.
Topical fluticasone propionate can be absorbed systemically, potentially leading to reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria.
This risk is heightened with the use of more potent corticosteroids, prolonged treatment, application to large surface areas, use of occlusive dressings, and in pediatric patients.
Pediatric patients may be more susceptible to systemic toxicity due to their larger skin surface area to body mass ratio and less developed skin barrier.
Regular evaluation for HPA axis suppression is recommended, particularly in patients at higher risk.
If HPA axis suppression is confirmed, gradual withdrawal of the drug, reduction in frequency of application, or substitution with a less potent corticosteroid should be considered.
Abrupt discontinuation after prolonged use may precipitate corticosteroid withdrawal symptoms.
Not for ophthalmic, oral, or intravaginal use.

How it Works (Mechanism of Action)

Fluticasone propionate is a potent synthetic corticosteroid that exerts its therapeutic effects primarily through its anti-inflammatory, antipruritic, and vasoconstrictive properties. It operates by binding to specific glucocorticoid receptors located within the cytoplasm of target cells. This binding leads to the translocation of the receptor-ligand complex into the nucleus, where it modulates gene transcription. Specifically, fluticasone propionate inhibits the synthesis of numerous inflammatory mediators, including prostaglandins and leukotrienes, by inducing the production of lipocortins (annexins) which, in turn, inhibit phospholipase A2. This action curtails the release of arachidonic acid, a precursor to these inflammatory agents. Furthermore, it suppresses the migration of neutrophils and macrophages to the site of inflammation, reduces capillary permeability, and stabilizes lysosomal membranes, collectively diminishing tissue swelling, irritation, and allergic reactions.